IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma
Glioma is characterized by strong immunosuppression and excessive angiogenesis. Based on existing reports, it can be speculated that the resistance to anti-angiogenic drug vascular endothelial growth factor A (VEGFA) antibody correlates to the induction of novel immune checkpoint indoleamine 2,3-dio...
Egile Nagusiak: | Zikang Xing, Xuewen Li, Zhen Ning Tony He, Xin Fang, Heng Liang, Chunxiang Kuang, Aiying Li, Qing Yang |
---|---|
Formatua: | Artikulua |
Hizkuntza: | English |
Argitaratua: |
MDPI AG
2024-06-01
|
Saila: | Pharmaceutics |
Gaiak: | |
Sarrera elektronikoa: | https://www.mdpi.com/1999-4923/16/7/870 |
Antzeko izenburuak
-
TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
nork: V. A. Kozlov, et al.
Argitaratua: (2017-07-01) -
On the nonredundant roles of TDO2 and IDO1
nork: Paolo ePuccetti
Argitaratua: (2014-10-01) -
Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
nork: Ganiyu Olatunbosun Arinola, et al.
Argitaratua: (2023-01-01) -
The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2)
nork: Chiara Suvieri, et al.
Argitaratua: (2024-11-01) -
What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past
nork: Yu Yao, et al.
Argitaratua: (2021-02-01)